Kyverna Extends $15M Loan Draw Window, Securing Future Capital Access
KYTX has more than doubled off its 52-week low of $2.52.
Summary
Kyverna Therapeutics amended its $150 million term loan facility with Oxford Finance, extending the draw period for the remaining $15 million of Term A loans until December 31, 2026. This provides the company with crucial financial flexibility and continued access to capital, supporting its ongoing clinical development and regulatory efforts, including the miv-cel BLA submission. The amendment also extends the availability of future tranches if the initial $15 million is fully utilized, though it includes an upfront fee and a non-utilization fee.
At the time of this announcement, KYTX was trading at $9.82 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $602.5M. The 52-week trading range was $2.52 to $13.67. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Wiseek News.